Low-dose ketamine guides
Clinical-context explainers for dosing, depression evidence, safety monitoring, and questions to bring to a prescriber.
Start here
Pick the guide that matches the question you need answered before treatment decisions.
Orient before treatment decisions
Use the complete guide for patient basics, treatment settings, and what low-dose language does and does not mean.
Separate dose, route, and monitoring
Review the dosing and administration guide when comparing titration, route of administration, and supervision requirements.
Read the evidence in context
Start with the depression guide for treatment-resistant depression evidence, remission goals, and measurement-based follow-up.
Guide library
Long-form resources for clinical context, monitoring, and patient questions.
Use these alongside a clinician
These guides describe how low-dose ketamine is studied and used. They do not replace evaluation by a qualified clinician familiar with your medical history.
More guides to explore
The Complete Guide to Low-Dose Ketamine Therapy
A comprehensive, evidence-based guide covering what low-dose ketamine is, how it works, all routes of administration, what patients can expect during treatment, efficacy data across conditions, safety considerations, and how to find qualified providers.
Read more
Ketamine for Depression: A Comprehensive Evidence-Based Guide
An in-depth clinical guide examining the evidence for low-dose ketamine in the treatment of major depressive disorder and treatment-resistant depression. Covers mechanisms of action, clinical trial data, response predictors, duration of effect, maintenance strategies, and cost-benefit analysis.
Read more
Ketamine Dosing and Administration: A Complete Clinical Guide
Reference guide to ketamine dosage across IV, oral, sublingual troche, and intranasal routes — weight-based dosing, titration, and route-specific protocols.
Read moreKeep reading
Recent guides and answers from across the site.
Expert Highlights Critical Ketamine Patient Considerations
Dr. Benjamin Brody discusses essential patient considerations for ketamine therapy at major psychiatric conference, covering safety protocols and clinical best practices.
Read more
Ketamine Bioavailability by Route: A Patient Comparison
How sublingual, oral, intranasal, IM, and IV ketamine compare on bioavailability and why route shapes both dose and effect. A patient-friendly low-dose framing.
Read more
Ketamine Troche Dosage: A Patient Reference Guide
Typical sublingual ketamine troche dosage ranges, how lozenges are dosed for depression and maintenance, what to know about increments, and key safety considerations.
Read more
Stanford Study: Drug Combo Extends Ketamine Anti-Suicide Effects
Stanford researchers report first drug combination to extend ketamine's rapid anti-suicide effects, potentially changing treatment protocols.
Read more
Low-Dose Ketamine for Insomnia: What Patients Should Know
How low-dose ketamine may influence insomnia and sleep quality, dosing considerations, evening timing, and safety basics for patients exploring sublingual protocols.
Read more
PHQ-9 and GAD-7 in Ketamine Dose Adjustment: A Patient Guide
Learn how PHQ-9 and GAD-7 assessments guide ketamine dose adjustments. Patient-focused guide to understanding symptom tracking and dosing decisions.
Read more
Boston Ketamine Clinics: A Window Into Real-World Use
CBS News spotlights Boston ketamine clinics treating mental health conditions. What real-world patient outcomes reveal about low-dose ketamine therapy.
Read more
What a Year of Experimental Depression Treatment Reveals
A Guardian journalist spent a year testing ketamine, TMS, and gut therapy for depression. Here's what their experience reveals about low-dose ketamine.
Read more
FDA Clears MIND1 Trial: NRX-101 Plus Robotic TMS for Suicidality
The FDA has cleared the MIND1 trial testing NRX-101 plus robotic TMS for suicidality in treatment-resistant depression. What it means for ketamine patients.
Read moreContact Low Dose Ketamine
Send corrections, provider questions, or advertising inquiries.